Effects of Sancai Lianmei Granules in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease: a randomized prospective open-label controlled trial Authors: Shengju Wang, Yuguo Xia, Xuke Han, Yang Gao, Xiaoran Zhang, Xingxing Lei, Xu Zhang, Qiu Chen Published: 2025 ABSTRACT ObjectiveSancai Lianmei granules (SCLMG) have demonstrated efficacy in improving glucolipid metabolism disorder, insulin resistance, and oxidative stress markers in both diabetic patients and rodent models. However, there is limited data available regarding the effect of SCLMG on human Metabolic dysfunction-associated fatty liver disease (MAFLD). This research aims to assess the impact of SCLMG on MAFLD in individuals with diabetes.Methods and research designSixty individuals diagnosed with type 2 diabetes mellitus (T2DM) and MAFLD were randomly allocated to one of two groups: the SCLMG group, which received standard treatment for T2DM along with SCLMG at a dose of 15 g three times daily, or the control group, which received standard treatment without SCLMG. The intervention lasted for 12 weeks. Alterations in liver fat content and liver sclerosis were evaluated using FibroScan. Secondary outcome measures included alterations in liver enzymes, fibrosis markers, advanced glycation end products AGEs, and metabolic parameters.ResultsWhen incorporated into the standard treatment regimen for MAFLD in diabetic patients, SCLMG exhibited an improvement in reducing hepatic steatosis (P = 0.048) while showing no substantial variations in liver stiffness (P = 0.762). Both the SCLMG and control groups revealed a substantial reduction in FibroScan readings at the end of the treatment period compared to baseline. The two groups exhibited substantial disparities in changes in liver enzymes (alanine aminotransferase (ALT) P = 0.018, aspartate aminotransferase (AST) P = 0.006, gamma-glutamyltranspeptidase (GGT) P < 0.001), skin autofluorescence (SAF) (P = 0.012), and metabolic parameters (P < 0.05). Nevertheless, there was a variation between the groups regarding serum procollagen III peptide (PIIIP) levels (P = 0.026), whereas changes in type Ⅳcollagen (CⅣ) (P = 0.265), hyaluronic acid (HA) (P = 0.199), laminin (LN) (P = 0.144), and high-density lipoprotein cholesterol (HDL-C) (P = 0.315) levels were not statistically significant.ConclusionsSCLMG is beneficial in regulating glucolipid metabolism and liver function. To a certain extent, SCLMG can improve liver steatosis and shows a tendency towards reducing liver sclerosis. Therefore, SCLMG has a good effect on individuals with T2DM and MAFLD.Trial registrationChiCTR2000033099||http://www.chictr.org.cn/ 20 May 2020.Registration details at https://www.chictr.org.cn/hvshowprojectEN.html?id=34391&v=1.5 Supplementary InformationThe online version contains supplementary material available at 10.1186/s12986-025-00996-z. Introduction Metabolic dysfunction-associated fatty liver disease (MAFLD), previously reported as non-alcoholic fatty liver disease (NAFLD) [1], is marked by ectopic fat buildup in the liver in the absence of excessive alcohol intake or other identifiable causes, making it the most widespread liver disease globally [2, 3]. This condition spans a range of severity, from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) [4]. MASH affects up to a quarter of MAFLD patients [5] and is linked to considerable morbidity and mortality. Significantly, MAFLD primarily affects individuals with type 2 diabetes mellitus (T2DM) [5]. The coexistence of T2DM in individuals with MAFLD elevates the risk of progressing to MASH, leading to a more severe prognosis [6, 7]. T2DM correlates with over a twofold rise in the risk of advanced fibrosis, complications associated with cirrhosis, and mortality from liver disease [8]. Numerous antidiabetic approaches, such as lifestyle adjustments, metformin, pioglitazone, and liraglutide, have been explored in treating MAFLD, yielding varying outcomes. However, the long-term sustainability of these treatments remains limited. Although Resmetirom has been recommended for treating MASH [9, 10], its global adoption remains limited for various reasons. Further research is needed to determine its efficacy in treating MAFLD in individuals with T2DM. This scenario highlights the need for developing effective interventions for patients with concurrent MAFLD and T2DM. Therefore, embracing a comprehensive strategy to tackle these interconnected conditions and adopting a holistic approach to addressing metabolic disease intervention could offer a promising therapeutic avenue [2]. For centuries, Chinese herbal medicine (CHM) has been a cornerstone of traditional healing practices in China and across Asia. One distinctive aspect of Chinese medicine involves the creation of formulations blending various herbs to address the diverse symptoms associated with specific ailments [11]. Earlier research has shown that these Traditional Chinese Medicine (TCM) formulations exhibit promising effectiveness in the treatment of MAFLD [12]. As a CHM formula, Sancai Lianmei granules (SCLMG) are commonly prescribed for treating diabetes. In previous clinical studies, SCLMG has been validated to exert hypoglycemic effects by ameliorating insulin resistance and lipid metabolism disorders [13, 14]. Animal experiments have shown that SCLMG can regulate blood lipids and oxidative stress markers in mice [15]. Considering the frequent coexistence of T2DM and MAFLD, there is limited data available on the impact of SCLMG on liver fat in individuals with T2DM. The main goal of this research was to examine the efficacy of a combined treatment regimen comprising SCLMG and metformin in reducing hepatic steatosis (CAP, Controlled attenuation parameter, which quantifies hepatic steatosis) and liver stiffness (LSM, Liver stiffness measurement, which assesses liver stiffness), as determined by FibroScan, in individuals diagnosed with T2DM and MAFLD. Additionally, the study dealt with comparing the efficacy of the combined SCLMG and metformin treatment against metformin monotherapy in reducing liver fibrosis biomarkers. The study also investigated the effect of these treatments on glucose regulation, oxidative stress, lipid metabolism, and biomarkers indicative of hepatocyte injury. Methodologies and research design Participants and study setting This trial was a randomized, prospective, open-label clinical study aimed at evaluating the effect of SCLMG (15 g, thrice daily) when added to standard treatment (comprising lifestyle intervention and metformin 0.5 g, thrice daily, in the SCLMG group) versus standard treatment alone (comprising lifestyle intervention and metformin 0.5 g, thrice daily, in the Control group) in individuals diagnosed with both T2DM and MAFLD. Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were quantified using FibroScan (Echosens, Paris, France). The research adhered to the Consolidated Standards of Reporting Trial guidelines. Participants were selected from the endocrine outpatient clinic and inpatient ward at the Hospital of Chengdu University of Traditional Chinese Medicine. Eligible individuals underwent screening before enrollment in the trial. This investigation was registered as a clinical trial (ChiCTR2000033099), and its protocol got approval from the institutional ethics review board (2020KL-004). All participants provided informed written consent before participation. Eligibility criteria Inclusion criteria comprised individuals aged 18 to 75 years with documented MAFLD and uncontrolled T2DM (HbA1c > 7.0% to < 9.0%) who provided written informed consent. Patients with hepatic steatosis (Historical documentation of steatosis either by imaging, blood biomarkers/scores, or histology) plus past or present evidence of metabolic risk factors that meet the criteria to diagnose MAFLD (detailed in Supplemental Table S1). Exclusion criteria included type 1 diabetes and severely uncontrolled diabetes (HbA1c > 10.0%), significant alcohol consumption (> 30 g/day within the past 10 years or > 10 g/day within the past year), evidence of other liver diseases (such as hepatitis B/C, autoimmune hepatitis, drug-induced liver disease on the basis of exposure and history, and biliary duct obstruction on the basis of imaging studies); history of gastrointestinal bypass surgery, recent initiation or alteration of antidiabetic drugs affecting liver steatosis (including insulin, thiazolidinediones, GLP-1 receptor agonists, or SGLT-2 inhibitors), evidence of hepatocellular carcinoma (based on ultrasonography or MRI findings), positive human immunodeficiency virus (HIV) status, active substance abuse, pregnancy or intention to conceive, and renal insufficiency (glomerular filtration rate < 90 mL/min/1.732). Randomization and allocation Concealment and study visits Following a thorough assessment during the baseline visit, eligible participants adhering to the inclusion and exclusion criteria were randomly assigned in a 1:1 ratio using a randomized digital table. They were allocated to receive either SCLMG (15 g, three times daily) plus standard treatment (comprising lifestyle intervention and three times daily metformin 0.5 g) for T2DM patients with MAFLD, or standard treatment alone (comprising lifestyle intervention and three times daily metformin 0.5 g) for T2DM patients with MAFLD. Lifestyle modification is a first-line strategy for managing T2DM and MAFLD. It includes physical activity (such as walking, gardening, and household chores for at least 30 min a day, 5 days a week), dietary adjustments (increased intake of vegetables, legumes, polyunsaturated fats, lean meat, and fish; restricted consumption of sugars, saturated fats, cholesterol, sodium, refined grains, ultra-processed foods; and evenly distributed meals throughout the day), and glycemic self-monitoring. Patients were instructed to maintain daily records of their diet, exercise, and glucose levels. The treatment allocation was open-label. Researchers responsible for analyzing imaging data were blinded to individual information and the sequence of allocation. While aware of the treatment group, the endocrinologists remained blinded to the imaging outcomes until the final data analysis. Participants attended follow-up visits at the outpatient endocrine clinic at week 12. Outcome measures Analyses were conducted at baseline and following 12 weeks of intervention. CAP and LSM were assessed using FibroScan 502 Touch, which provides evidence-based noninvasive liver steatosis and fibrosis measurements, respectively. The FibroScan procedure was conducted as described in the literature [16]. The CAP and LSM values were reported in dB/m and kPa, respectively. The cut-off values for diagnosing various degrees of liver steatosis using CAP were ≥ 11% (238 dB/m), ≥ 34% (259 dB/m), and ≥ 67% (292 dB/m), corresponding to increasing severity. Fibrosis staging was based on LSM cut-off values: ≥ F1 (7.3 kPa), ≥ F2 (9.7 kPa), ≥ F3 (12.4 kPa), and F4 (17.5 kPa), respectively. Advanced glycation end products (AGEs) were assessed through skin autofluorescence (SAF) analysis. Skin AGEs were evaluated using an autofluorescence reader (Hefei Institutes of Physical Science, Chinese Academy of Sciences) following a 2-3-min measurement of the left volar forearm [17, 18]. Serum markers of fibrosis procollagen III peptide (PIIIP), type Ⅳ collagen (CⅣ), hyaluronic acid (HA), laminin (LN), and liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (GGT) were obtained. Additionally, levels of glucose, total cholesterol (TC), triacylglycerols (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), HbA1c, and insulin were obtained. Insulin sensitivity was assessed using the homeostatic model assessment of insulin resistance (HOMA-IR = (FPG × FINS)/22.5, where FPG depicts fasting plasma glucose and FINS depicts fasting plasma insulin). Statistical analyses A sample size of 30 participants per treatment group was determined to attain a ≥ 90% statistical power for the primary endpoints, accounting for a dropout rate of ≤ 10% and assuming a relative reduction of 30% liver fat (CAP) for standard treatment combination of SCLMG compared to standard treatment alone for T2DM patients with MAFLD. All statistical analyses were conducted utilizing SPSS 20.0 software. Between-group comparisons for categorical variables were performed utilizing the χ2 test or Fisher exact test. Variations between continuous variables were assessed utilizing the independent samples t-test or Wilcoxon-Mann-Whitney U test. Additional analyses of primary and secondary outcomes within treatment groups were conducted by means of two-tailed independent sample t-tests, paired t-tests, or nonparametric tests as appropriate. P < 0.05 (two-tailed) was deemed statistically significant. Results Clinical features Out of the 78 individuals screened, 11 were found to be ineligible, and seven withdrew from participation due to other reasons. The remaining 60 patients diagnosed with T2DM and MAFLD were randomly allocated to receive either SCLMG (15 g, three times daily) combination of standard treatment for T2DM patients with MAFLD (SCLMG group) or standard treatment for T2DM patients with MAFLD alone (control group). In the treatment group, 26 participants completed the research, with three lost to follow-up and one discontinued taking medicines. In the control group, 28 participants completed the research, with two lost to follow-up (Fig. 1). Both groups exhibited similar baseline characteristics (Table 1). Fig. 1Derivation of the study cohort. SCLMG group, control group Derivation of the study cohort. SCLMG group, control group Table 1Participant characteristics at baselineControl groupSCLMG groupP valueGender (male/female), n (%)28(19/9)26(13/13)0.182Age (years), mean ± SD52.7 ± 8.956.9 ± 8.90.086Duration (years), mean ± SD3.2 ± 3.04.7 ± 4.20.140Height (cm), mean ± SD164.9 ± 9.4162.4 ± 9.00.315Weight (kg), mean ± SD70.5 ± 11.666.9 ± 10.90.248BMI (kg/m2), mean ± SD25.8 ± 2.425.3 ± 2.70.494SBP (mmHg), mean ± SD126.3 ± 10.4127.4 ± 16.50.766DBP (mmHg), mean ± SD83.4 ± 7.780.0 ± 12.00.221Complications (yes/no), n (%)28(13/15)26(14/12)0.586ALT (IU/L), mean ± SD34.5 ± 12.338.3 ± 18.20.376AST (IU/L), mean ± SD27.4 ± 4.431.8 ± 14.30.145GGT (U/L), mean ± SD32.5 ± 18.031.0 ± 16.50.745BUN (mmol/L), mean ± SD5.3 ± 1.35.6 ± 1.70.518Cr (umol/L), mean ± SD58.5 ± 14.459.3 ± 14.90.853UA (umol/L), mean ± SD321.0 ± 103.1343.4 ± 85.20.391TC (mmol/L), mean ± SD4.6 ± 1.54.6 ± 1.10.948TG (mmol/L), mean ± SD2.5 ± 2.02.4 ± 1.50.724HDL-C (mmol/L), mean ± SD0.9 ± 0.20.9 ± 0.10.866LDL-C (mmol/L), mean ± SD2.8 ± 1.02.9 ± 0.80.730FPG (mmol/L), mean ± SD8.2 ± 2.68.4 ± 2.00.754HbA1c (%), mean ± SD8.0 ± 0.78.1 ± 0.70.378FINS (mU/L), mean ± SD10.2 ± 4.712.4 ± 8.40.241HOMA-IR, mean ± SD1.1 ± 0.61.3 ± 0.70.363SAF, mean ± SD79.2 ± 9.980.3 ± 9.80.680PIIIP (ng/ml), mean ± SD26.8 ± 2.828.4 ± 3.20.058CⅣ (ng/ml), mean ± SD25.0 ± 3.626.8 ± 6.40.205HA (ng/ml), mean ± SD79.9 ± 8.785.7 ± 13.80.073LN (ng/ml), mean ± SD37.0 ± 6.440.7 ± 10.40.127CAP (dB/m), mean ± SD274.0 ± 14.4273.9 ± 15.40.984LSM (kPa), mean ± SD6.2 ± 0.76.6 ± 1.00.118Notes: Data are presented as n (%) or mean ± SD. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltranspeptidase; BUN: blood urea nitrogen; Cr: serum creatinine; UA: serum uric acid; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; FINS: fasting plasma insulin; HOMA-IR: homeostasis model assessment of insulin resistance; SAF: skin autofluorescence; PIIIP: serum procollagen III peptide; CⅣ: type Ⅳ collagen; HA: hyaluronic acid; LN: laminin; CAP: controlled attenuation parameter; LSM: liver stiffness measurement Table 1Participant characteristics at baselineControl groupSCLMG groupP valueGender (male/female), n (%)28(19/9)26(13/13)0.182Age (years), mean ± SD52.7 ± 8.956.9 ± 8.90.086Duration (years), mean ± SD3.2 ± 3.04.7 ± 4.20.140Height (cm), mean ± SD164.9 ± 9.4162.4 ± 9.00.315Weight (kg), mean ± SD70.5 ± 11.666.9 ± 10.90.248BMI (kg/m2), mean ± SD25.8 ± 2.425.3 ± 2.70.494SBP (mmHg), mean ± SD126.3 ± 10.4127.4 ± 16.50.766DBP (mmHg), mean ± SD83.4 ± 7.780.0 ± 12.00.221Complications (yes/no), n (%)28(13/15)26(14/12)0.586ALT (IU/L), mean ± SD34.5 ± 12.338.3 ± 18.20.376AST (IU/L), mean ± SD27.4 ± 4.431.8 ± 14.30.145GGT (U/L), mean ± SD32.5 ± 18.031.0 ± 16.50.745BUN (mmol/L), mean ± SD5.3 ± 1.35.6 ± 1.70.518Cr (umol/L), mean ± SD58.5 ± 14.459.3 ± 14.90.853UA (umol/L), mean ± SD321.0 ± 103.1343.4 ± 85.20.391TC (mmol/L), mean ± SD4.6 ± 1.54.6 ± 1.10.948TG (mmol/L), mean ± SD2.5 ± 2.02.4 ± 1.50.724HDL-C (mmol/L), mean ± SD0.9 ± 0.20.9 ± 0.10.866LDL-C (mmol/L), mean ± SD2.8 ± 1.02.9 ± 0.80.730FPG (mmol/L), mean ± SD8.2 ± 2.68.4 ± 2.00.754HbA1c (%), mean ± SD8.0 ± 0.78.1 ± 0.70.378FINS (mU/L), mean ± SD10.2 ± 4.712.4 ± 8.40.241HOMA-IR, mean ± SD1.1 ± 0.61.3 ± 0.70.363SAF, mean ± SD79.2 ± 9.980.3 ± 9.80.680PIIIP (ng/ml), mean ± SD26.8 ± 2.828.4 ± 3.20.058CⅣ (ng/ml), mean ± SD25.0 ± 3.626.8 ± 6.40.205HA (ng/ml), mean ± SD79.9 ± 8.785.7 ± 13.80.073LN (ng/ml), mean ± SD37.0 ± 6.440.7 ± 10.40.127CAP (dB/m), mean ± SD274.0 ± 14.4273.9 ± 15.40.984LSM (kPa), mean ± SD6.2 ± 0.76.6 ± 1.00.118Notes: Data are presented as n (%) or mean ± SD. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltranspeptidase; BUN: blood urea nitrogen; Cr: serum creatinine; UA: serum uric acid; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; FINS: fasting plasma insulin; HOMA-IR: homeostasis model assessment of insulin resistance; SAF: skin autofluorescence; PIIIP: serum procollagen III peptide; CⅣ: type Ⅳ collagen; HA: hyaluronic acid; LN: laminin; CAP: controlled attenuation parameter; LSM: liver stiffness measurement Participant characteristics at baseline Notes: Data are presented as n (%) or mean ± SD. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltranspeptidase; BUN: blood urea nitrogen; Cr: serum creatinine; UA: serum uric acid; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; FINS: fasting plasma insulin; HOMA-IR: homeostasis model assessment of insulin resistance; SAF: skin autofluorescence; PIIIP: serum procollagen III peptide; CⅣ: type Ⅳ collagen; HA: hyaluronic acid; LN: laminin; CAP: controlled attenuation parameter; LSM: liver stiffness measurement Hepatic steatosis and hepatic stiffness Liver fat (CAP) was evaluated using FibroScan. Both the SCLMG group and the control group displayed a substantial reduction in liver CAP from baseline to 12 weeks (Table 2). Following 12 weeks of treatment, the SCLMG group exhibited a greater reduction in liver CAP relative to the control group. Table 2Changes in CAP and LSM (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueCAP (dB/m)274.0 ± 14.4272.6 ± 14.3< 0.001273.9 ± 15.4264.7 ± 14.3< 0.0010.048LSM (kPa)6.2 ± 0.76.1 ± 0.7< 0.0016.6 ± 1.06.0 ± 0.8< 0.0010.762 Table 2Changes in CAP and LSM (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueCAP (dB/m)274.0 ± 14.4272.6 ± 14.3< 0.001273.9 ± 15.4264.7 ± 14.3< 0.0010.048LSM (kPa)6.2 ± 0.76.1 ± 0.7< 0.0016.6 ± 1.06.0 ± 0.8< 0.0010.762 Changes in CAP and LSM (mean ± SD) Liver stiffness measurements were obtained via transient elastography at baseline and week 12 for participants who were randomized to receive SCLMG and those who were not. Significant reduction in liver stiffness, as measured by FibroScan, was observed from baseline to week 12 in both SCLMG-treated and untreated patients. Additionally, there was a trend towards decreased liver stiffness by FibroScan from baseline to week 12 in individuals treated with SCLMG, whereas no considerable differences were found in the control group (Table 2). Liver enzymes and fibrosis biomarkers Table 3 indicates substantial variations between the two groups regarding alterations in serum ALT and AST levels. Furthermore, GGT levels exhibited a significant decrease in the SCLMG group, whereas no substantial variation was found in GGT levels between baseline and post-treatment in the control group. Following the 12-week intervention, patients receiving SCLMG experienced a greater reduction in ALT, AST, and GGT levels in contrast to the control group (Table 3). Table 3Changes in liver enzymes (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueALT (IU/L)34.5 ± 12.331.0 ± 12.6< 0.00138.3 ± 18.224.0 ± 7.7< 0.0010.018AST (IU/L)27.4 ± 4.424.8 ± 4.7< 0.00131.8 ± 14.320.7 ± 5.7< 0.0010.006GGT (U/L)32.5 ± 18.031.6 ± 16.10.30431.0 ± 16.518.3 ± 4.5< 0.001< 0.001 Table 3Changes in liver enzymes (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueALT (IU/L)34.5 ± 12.331.0 ± 12.6< 0.00138.3 ± 18.224.0 ± 7.7< 0.0010.018AST (IU/L)27.4 ± 4.424.8 ± 4.7< 0.00131.8 ± 14.320.7 ± 5.7< 0.0010.006GGT (U/L)32.5 ± 18.031.6 ± 16.10.30431.0 ± 16.518.3 ± 4.5< 0.001< 0.001 Changes in liver enzymes (mean ± SD) Compared to the baseline, the SCLMG group exhibited significant differences in end-of-treatment levels of PIIIP, CⅣ, HA, and LN. In contrast, the control group displayed variations in serum levels of PIIIP, CⅣ, and LN but not in HA levels. After 12 weeks of treatment, the SCLMG group demonstrated a more decrease in PIIIP levels relative to the control group. Additionally, although the SCLMG group displayed reduced levels of CⅣ, HA, and LN relative to the control group, these variations were not statistically significant (Table 4). Table 4Changes in markers of liver fibrosis (mean ± SD)Markers (ng/ml)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valuePIIIP26.8 ± 2.826.7 ± 2.70.00828.4 ± 3.224.9 ± 2.8< 0.0010.026CⅣ25.0 ± 3.624.5 ± 3.60.03226.8 ± 6.423.1 ± 5.6< 0.0010.265HA79.9 ± 8.779.7 ± 8.70.13085.7 ± 13.876.3 ± 10.7< 0.0010.199LN37.0 ± 6.436.8 ± 6.40.00240.7 ± 10.433.7 ± 8.8< 0.0010.144 Table 4Changes in markers of liver fibrosis (mean ± SD)Markers (ng/ml)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valuePIIIP26.8 ± 2.826.7 ± 2.70.00828.4 ± 3.224.9 ± 2.8< 0.0010.026CⅣ25.0 ± 3.624.5 ± 3.60.03226.8 ± 6.423.1 ± 5.6< 0.0010.265HA79.9 ± 8.779.7 ± 8.70.13085.7 ± 13.876.3 ± 10.7< 0.0010.199LN37.0 ± 6.436.8 ± 6.40.00240.7 ± 10.433.7 ± 8.8< 0.0010.144 Changes in markers of liver fibrosis (mean ± SD) Advanced glycation end products (AGEs) changes Both the SCLMG and control groups displayed a substantial decrease in AGE concentrations. At the end of the treatment period, a variation in AGE concentrations was noted between the SCLMG group and the control group (Table 5). Table 5Changes in ages (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueSAF79.2 ± 9.976.4 ± 9.8< 0.00180.3 ± 9.869.8 ± 8.6< 0.0010.012 Table 5Changes in ages (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueSAF79.2 ± 9.976.4 ± 9.8< 0.00180.3 ± 9.869.8 ± 8.6< 0.0010.012 Changes in ages (mean ± SD) Lipid metabolism parameters After treatment, both the SCLMG and control groups showed reduced TC, TG, and LDL-C levels and enhanced HDL-C levels. At the end of treatment, individuals administered SCLMG exhibited a more reduction in TC, TG, and LDL-C levels relative to those in the control group. Nevertheless, no substantial variations were noted in HDL-C levels between the two groups (Table 6). Table 6Changes in lipid metabolism parameters (mean ± SD)Lipid (mmol/L)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueTC4.6 ± 1.54.0 ± 1.00.0024.6 ± 1.13.2 ± 0.7< 0.0010.001TG2.5 ± 2.02.3 ± 1.8< 0.0012.4 ± 1.51.5 ± 0.6< 0.0010.041HDL-C0.9 ± 0.21.0 ± 0.20.0020.9 ± 0.11.0 ± 0.1< 0.0010.315LDL-C2.8 ± 1.02.5 ± 0.9< 0.0012.9 ± 0.82.1 ± 0.4< 0.0010.025 Table 6Changes in lipid metabolism parameters (mean ± SD)Lipid (mmol/L)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueTC4.6 ± 1.54.0 ± 1.00.0024.6 ± 1.13.2 ± 0.7< 0.0010.001TG2.5 ± 2.02.3 ± 1.8< 0.0012.4 ± 1.51.5 ± 0.6< 0.0010.041HDL-C0.9 ± 0.21.0 ± 0.20.0020.9 ± 0.11.0 ± 0.1< 0.0010.315LDL-C2.8 ± 1.02.5 ± 0.9< 0.0012.9 ± 0.82.1 ± 0.4< 0.0010.025 Changes in lipid metabolism parameters (mean ± SD) Metabolic parameters Both the SCLMG and control groups exhibited a substantial decrease in fasting plasma glucose (FPG) and HbA1c levels. However, in the post-treatment phase, participants using SCLMG demonstrated more reduction in FPG and HbA1c levels in contrast to those in the control group (Table 7). Additionally, SCLMG-treated patients experienced a greater reduction in weight and BMI levels relative to the control group. Furthermore, FINS levels and HOMA-IR values exhibited more reductions in the SCLMG group. Table 7Changes in metabolic parameters (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueFPG (mmol/L)8.2 ± 2.66.7 ± 1.10.0018.4 ± 2.05.7 ± 0.5< 0.001< 0.001HbA1c (%)8.0 ± 0.77.7 ± 0.7< 0.0018.1 ± 0.77.1 ± 0.5< 0.001< 0.001FINS (mU/L)10.2 ± 4.79.5 ± 4.6< 0.00112.4 ± 8.47.3 ± 2.9< 0.0010.042Weight (kg)70.5 ± 11.669.4 ± 11.5< 0.00166.9 ± 10.963.6 ± 9.3< 0.0010.049BMI (kg/m2)25.8 ± 2.425.4 ± 2.4< 0.00125.3 ± 2.724.0 ± 2.0< 0.0010.033HOMA-IR1.1 ± 0.60.9 ± 0.5< 0.0011.3 ± 0.70.5 ± 0.4< 0.0010.010 Table 7Changes in metabolic parameters (mean ± SD)Control group (28)SCLMG group (26)Difference between groupBaselinePosttreatmentP valueBaselinePosttreatmentP valueP valueFPG (mmol/L)8.2 ± 2.66.7 ± 1.10.0018.4 ± 2.05.7 ± 0.5< 0.001< 0.001HbA1c (%)8.0 ± 0.77.7 ± 0.7< 0.0018.1 ± 0.77.1 ± 0.5< 0.001< 0.001FINS (mU/L)10.2 ± 4.79.5 ± 4.6< 0.00112.4 ± 8.47.3 ± 2.9< 0.0010.042Weight (kg)70.5 ± 11.669.4 ± 11.5< 0.00166.9 ± 10.963.6 ± 9.3< 0.0010.049BMI (kg/m2)25.8 ± 2.425.4 ± 2.4< 0.00125.3 ± 2.724.0 ± 2.0< 0.0010.033HOMA-IR1.1 ± 0.60.9 ± 0.5< 0.0011.3 ± 0.70.5 ± 0.4< 0.0010.010 Changes in metabolic parameters (mean ± SD) Safety During the study, several adverse events were recorded. One participant from the SCLMG group developed severe diarrhea within a week of starting the medication and opted to discontinue participation. Other adverse events reported were predominantly mild or moderate in nature and resolved completely within a few days. Importantly, both treatment groups did not exhibit significant alterations in serum creatinine levels. Discussion The present research represents the initial investigation into the impact of SCLMG on individuals with T2DM and MAFLD. Through this randomized controlled trial, compelling evidence is presented regarding the effect of SCLMG on liver steatosis, as assessed by CAP, in individuals with T2DM and MAFLD. The combined 12-week intervention of SCLMG alongside standard treatment resulted in a significant reduction in liver fat content among individuals with T2DM and MAFLD. Therefore, the research successfully achieved its primary objective and demonstrates the potential of this dual therapy to improve liver steatosis in diabetic patients with MAFLD. FibroScan, a cost-effective technique widely utilized for noninvasive assessment, is commonly employed to evaluate liver steatosis and fibrosis. It can accurately quantify and stage hepatic steatosis and stiffness in patients with MAFLD. In this trial involving individuals with both T2DM and MAFLD, a substantial variation was noted between the SCLMG group and the control group regarding the primary endpoint, which entailed a reduction in liver fat content as measured by FibroScan. Specifically, there was a statistically significant reduction in liver fat content favoring the SCLMG group. However, while participants receiving SCLMG in combination with standard treatment demonstrated a reduction in liver fibrosis as assessed by FibroScan compared to those receiving standard treatment alone, this difference did not reach statistical significance. Hepatic fibrosis was also assessed by assessing fibrosis markers, encompassing PIIIP, CⅣ, HA, and LN. These markers are clinically utilized for evaluating the extent of liver sclerosis in MAFLD participants [19, 20]. PIIIP, CⅣ, HA, and LN levels were observed to be more reduced in the SCLMG group, suggesting that SCLMG has a trend toward improving liver stiffness. No substantial difference was noted in the levels of CⅣ, HA, and LN between these two groups after the intervention, while a substantial reduction in PIIIP was noted in both groups. This suggests that PIIIP may be more sensitive to minor alterations in fibrosis compared to CⅣ, HA, and LN. Nevertheless, long-term monitoring is warranted to accurately assess improvements in liver stiffness. One potential reason is that a small proportion of participants (13% overall) in our study exhibited a high degree of liver sclerosis (≥ 7.3 kPa) at baseline, which could have hindered the detection of a reduction in liver fibrosis. Another possible explanation for the absence of a substantial reduction in liver cirrhosis in this trial is the 12-week timepoint. Studies have indicated that no improvement in liver fibrosis was observed even after 72 weeks [21]. While the SCLMG group demonstrated a trend toward reduction in liver stiffness as measured by FibroScan from baseline to week 12, this suggests that a considerably longer duration may be necessary to assess an improvement in liver sclerosis. Considering persistent hyperglycemia in individuals with diabetes, along with hyperlipidemia and oxidative stress, there is an accumulation of AGEs. In this trial, an autofluorescence reader was utilized to measure SAF for estimating AGE concentration, as previously described in the literature [18]. Prior research has demonstrated a strong correlation between SAF and fatty liver [18]. AGEs were detected as a marker of oxidative stress in this study. A decrease in AGE concentrations was found in both the SCLMG group and the control group, with a more reduction favoring the SCLMG group. This suggests that SCLMG may have the ability to regulate oxidative stress in individuals with diabetes having MAFLD. Given that hepatic lipotoxicity is a prominent driving force of liver steatosis and sclerosis progression, and considering that both steatosis and MASH are reversible conditions [22], our results demonstrating a decrease in serum fat concentration between the SCLMG and control groups suggest the potential to reverse steatosis and decay cirrhosis progression. A substantial reduction in serum fat levels was observed in favor of the SCLMG group. Furthermore, the impact of SCLMG on liver fat was accompanied by a reduction in body weight, a change not as prominent in the control group. MAFLD prevalence is considerably higher in individuals with obesity. Additionally, excessive caloric intake worsens MAFLD by contributing to triglyceride accumulation and damaging free fatty acid metabolism [23, 24]. Therefore, a decrease in body weight is expected to correlate with liver fat reduction. Consequently, weight loss is a well-established intervention for MAFLD [6]. Liver disease, including MAFLD, correlates with elevated liver enzyme levels [25, 26]. Consequently, a decrease in enzyme concentrations may suggest an improvement in liver function. Consistent with the findings, reduced liver fat and body weight were accompanied by a decline in ALT and AST concentrations. Furthermore, GGT levels were notably reduced in the SCLMG group, whereas no statistically significant difference was observed between baseline and post-treatment in the control group. This suggests that SCLMG may contribute to improved liver function and have a beneficial effect on MAFLD. This improvement could potentially be attributed to decreased lipotoxicity, oxidative stress, and glucotoxicity, as evidenced by reduced liver fat content linked to diminished GGT levels. The association between T2DM and MAFLD can be delineated through a range of metabolic changes, such as insulin resistance (IR), impaired lipid profile, and oxidative stress. These factors collectively contribute to fat accumulation, subsequently leading to hyperinsulinemia. Notably, elevated IR emerged as the most influential predictive factor for MAFLD, with studies demonstrating a robust correlation between serum insulin levels and ballooning and hepatic lobular inflammation [27, 28]. Additionally, both groups exhibited an ameliorative effect on diabetes. Treatment with or without SCLMG resulted in the expected reductions in HbA1c, FINS, and HOMA-IR values. However, these alterations favored the SCLMG group. These effects align with the established mechanism of action. While SCLMG did not lead to a substantial improvement in liver sclerosis relative to the control group, a decrease in liver fat content was observed. This, coupled with other findings such as weight loss, improved glycemic control, and reductions in liver enzymes, may suggest that SCLMG treatment holds promise for positively affecting disease activity and metabolic profile in diabetic individuals with MAFLD. Multitarget agents or combinations of drugs are hypothesized to yield twice the beneficial effects compared to monotherapy. Currently, numerous studies are underway to explore new promising pharmacological drugs for MAFLD and assess the effects of antidiabetic agents on liver function. Pervious studies have shown that TCM, including CHM and Qigong exercises, may improve muscle strength in older adults with sarcopenia [29, 30]. As sarcopenia frequently coexists with MAFLD and T2DM, further investigation is warranted to determine whether SCLMG can enhance muscle strength in individuals with or without these conditions. In conclusion, the findings of this trial displayed that SCLMG ameliorated liver steatosis in persons with T2DM and MAFLD under adequate glycemic control, lipid profile improvement, IR improvement, and weight loss. Compared to standard treatment alone, SCLMG led to greater improvement in liver function, along with a reduction in AGE levels. This study provided evidence regarding the effect of alternative agents on diabetic patients with MAFLD, potentially guiding pharmacotherapeutic approaches for individuals with T2DM and MAFLD. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1